FDA Requires New Boxed Warnings on JAK Inhibitors, Places Restrictions on Use

The impact on patients and the administrative burden on practices will likely increase, says Victoria Ruffing, RN-BC, the director of patient education at the Johns Hopkins Arthritis Center, Baltimore, adjunct faculty at the Johns Hopkins School of Nursing and an associate editor of The Rheumatologist. “I foresee even greater challenges for prior authorizations. Insurance companies will likely try to force the use of two TNFs before agreeing to a JAK inhibitor,” she says. “Also, many patients are going to be hesitant to start JAK inhibitors when they hear about this.”

References

FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions. U.S. Food & Drug Administration. Drug Safety Communication. 2021 Sep 1.
FDA approves Boxed Warning about increased risk of blood clots and death with higher dose of arthritis and ulcerative colitis medicine tofacitinib (Xeljanz, Xeljanz XR). U.S. Food & Drug Administration. Drug Safety Communication. 2019 Jul 26.

A decade after JAK inhibitors were approved, this EULAR 2022 session looks at whether the drugs have lived up to expectations.

ACR CONVERGENCE 2021—The ACR Convergence 2021 meeting reflected the continued advancement of science and practical research in the field of rheumatoid arthritis (RA). Among the most important topics this year in RA was the evolution of the risk-benefit profile of Janus kinase (JAK) inhibitors, for which new safety data emerged in a series of related…

Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and small molecule inhibitor drugs…

Highlights from the 2017 EULAR Congress MADRID—Tofacitinib (a JAK inhibitor) used with methotrexate (MTX) is not inferior to adalimumab (a TNF inhibitor) plus MTX in rheumatoid arthritis (RA) patients who’ve had an inadequate response to MTX alone, according to results of a Phase 3B/4 trial presented in a session at the Annual European Congress of…

JAK Inhibitors: Are All Promises Fulfilled?

Updates on JAK Inhibitor Safety, COVID-19 Vaccination in Immunosuppressed Patients & More

Rheumatology Drugs at a Glance, Part 3: Rheumatoid Arthritis

Tofacitinib with Methotrexate Not Inferior to Adalimumab with Methotrexate

Related Articles